Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (HKG:2315)
Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
59.50
+5.55 (10.29%)
At close: Mar 10, 2026

HKG:2315 Ratios and Metrics

Millions HKD. Fiscal year is Jan - Dec.
Fiscal Year
CurrentFY 2025 FY 2024 FY 2023 FY 2022 FY 2021 2020
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 2020
Market Capitalization
35,28023,5853,3954,78510,245-
Upgrade
Market Cap Growth
982.52%594.71%-29.05%-53.29%--
Upgrade
Enterprise Value
35,42423,7293,5624,68210,003-
Upgrade
Last Close Price
53.9535.308.5011.9825.65-
Upgrade
PE Ratio
112.75122.3795.11---
Upgrade
PS Ratio
22.9915.373.256.0616.97-
Upgrade
PB Ratio
--3.805.507.87-
Upgrade
P/TBV Ratio
--3.925.738.12-
Upgrade
P/FCF Ratio
--18.32---
Upgrade
P/OCF Ratio
--15.10---
Upgrade
EV/Sales Ratio
23.0915.473.415.9316.57-
Upgrade
EV/EBITDA Ratio
97.2165.1211.58---
Upgrade
EV/EBIT Ratio
168.80113.0822.29---
Upgrade
EV/FCF Ratio
--19.23---
Upgrade
Debt / Equity Ratio
--0.680.690.360.07
Upgrade
Debt / EBITDA Ratio
--1.80---
Upgrade
Debt / FCF Ratio
--3.28---
Upgrade
Net Debt / Equity Ratio
--0.190.14-0.20-0.39
Upgrade
Net Debt / EBITDA Ratio
--0.55-0.710.491.16
Upgrade
Net Debt / FCF Ratio
--0.91-0.540.420.86
Upgrade
Asset Turnover
--0.400.270.210.15
Upgrade
Inventory Turnover
--26.8012.256.096.11
Upgrade
Quick Ratio
--1.221.011.251.55
Upgrade
Current Ratio
--1.531.251.521.96
Upgrade
Return on Equity (ROE)
--4.12%-39.45%-50.12%-40.27%
Upgrade
Return on Assets (ROA)
--3.86%-6.94%-14.81%-14.02%
Upgrade
Return on Invested Capital (ROIC)
33.93%34.82%12.36%-31.99%-71.53%-76.89%
Upgrade
Return on Capital Employed (ROCE)
--8.00%-15.60%-27.60%-28.00%
Upgrade
Earnings Yield
0.55%0.82%1.05%-8.82%-6.64%-
Upgrade
FCF Yield
--5.46%-4.68%-6.00%-
Upgrade
Buyback Yield / Dilution
-1.20%-1.20%0.08%-4.54%-5.13%-180.82%
Upgrade
Source: S&P Capital IQ. Standard template. Financial Sources.